ReviewExpert review of vaccines2007
Enhancing DNA vaccine potency by modifying the properties of antigen-presenting cells.
Review in Expert review of vaccines, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 67 citations in OpenAlex.
- Improved efficacy of therapeutic HPV DNA vaccine using intramuscular injection with electroporation compared to conventional needle and needle-free jet injector methods.Cell & bioscience · 2024Article
- Characterization of recombinant gorilla adenovirus HPV therapeutic vaccine PRGN-2009.JCI insight · 2021Article
- Therapeutic vaccines for high-risk HPV-associated diseases.Papillomavirus research (Amsterdam, Netherlands) · 2018Review
- Co-Delivery of Imiquimod and Plasmid DNA via an Amphiphilic pH-Responsive Star Polymer that Forms Unimolecular Micelles in Water.Polymers · 2016Article
- Current state in the development of candidate therapeutic HPV vaccines.Expert review of vaccines · 2016Review
- Co-administration with DNA encoding papillomavirus capsid proteins enhances the antitumor effects generated by therapeutic HPV DNA vaccination.Cell & bioscience · 2015Article
- Modulation of hepatitis C virus core DNA vaccine immune responses by co-immunization with CC-chemokine ligand 20 (CCL20) gene as immunoadjuvant.Molecular biology reports · 2014Article
- Enhancement of Immune Responses by Co-delivery of CCL19/MIP-3beta Chemokine Plasmid With HCV Core DNA/Protein Immunization.Hepatitis monthly · 2014Article
- The effects of HIV Tat DNA on regulating the immune response of HIV DNA vaccine in mice.Virology journal · 2013Article
- Innovative DNA vaccine to break immune tolerance against tumor self-antigen.Human gene therapy · 2013Article
- Article
- Perspective for prophylaxis and treatment of cervical cancer: an immunological approach.International reviews of immunology · 2012Review
- Genetic targeting of the active transcription factor XBP1s to dendritic cells potentiates vaccine-induced prophylactic and therapeutic antitumor immunity.Molecular therapy : the journal of the American Society of Gene Therapy · 2012Article
- Review
- Vascular disrupting agent DMXAA enhances the antitumor effects generated by therapeutic HPV DNA vaccines.Journal of biomedical science · 2011Article
- Innovative DNA vaccine for human papillomavirus (HPV)-associated head and neck cancer.Gene therapy · 2011Article
- Prostate cancer as a model for tumour immunotherapy.Nature reviews. Immunology · 2010Review
- Treatment with imiquimod enhances antitumor immunity induced by therapeutic HPV DNA vaccination.Journal of biomedical science · 2010Article
- Article
- Immunotherapy for cervical cancer: Research status and clinical potential.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2010Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
DNA vaccines represent a potentially promising approach for antigen-specific immunotherapy. Advances in our knowledge of the adaptive immune system have indicated that professional antigen-presenting cells, especially dendritic cells (DCs), play a key role in the generation of antigen-specific immune responses. Thus, the modification of the properties of DCs represents an important strategy for enhancing the potency of DNA vaccines. This review discusses strategies to increase the number of antigen-expressing DCs, enhance antigen expression, processing and presentation in DCs, promote the activation and function of DCs, and improve DC and T-cell interaction, in order to optimize DNA vaccine-elicited immune responses. Continuing progress in our understanding of DC and T-cell biology serves as a foundation for further improvement of DNA vaccine potency, which may lead to future clinical applications of DNA vaccines for the control of infectious diseases and malignancies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.